Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06873724 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of SPY003-207 in Healthy Volunteers

StatusActive, Not Recruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial status: Recruiting to Active, Not Recruiting Enrollment target: estimated 64 to confirmed 59 · Study sites: 1 to 2 · Primary and study completion dates: Dec 2026 to Nov 18, 2026 · 2 morev3 Show 5 more changesShow less
    • Enrollment target: estimated 64 to confirmed 59
    • Study sites: 1 to 2
    • Primary and study completion dates: Dec 2026 to Nov 18, 2026
    • Study arms: 2 to 6
    • Study title expanded, about 3 words

    See this version in full on ClinicalTrials.gov ↗

  2. Study title revisedv2 See this version in full on ClinicalTrials.gov ↗
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a Phase 1, randomized, double-blind, placebo-controlled, single dose, first in human safety, tolerability, and pharmacokinetic study of SPY003-207 in healthy participants.
Trial Details
NCT Number NCT06873724
Lead Sponsor Spyre Therapeutics, Inc.
Collaborators: Altasciences Company Inc.
Conditions Healthy
Enrollment 59 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov